Calls for transparency around data disclosure only likely to continue to increase. #ISMPP
Collaboration key to ensuring transparency across all medical publications - whoever is the sponsor, industry or academia. #ISMPP
Looking forward to the 10th Annual Meeting. Come see us at the Envision Pharma Group booth. #ISMPP
GSK's vision is to have an independent data custodian, act to assess data research proposals and allow access as appropriate #ismppam13
We as a profession need to ensure that data analysis based research shows the relevance and how done to cut down the noise #ismppam13
Newer metrics are coming, we just need to work out what serves us best as the new industry standard. #ismppam13
Despite the limitations, there is still a reliance on impact factor. Other systems - scopus, Google Scholar provide rankings #ismppam13
Open access is rapidly developing, but last year 88% of published work was behind subscription firewalls. #ismppam13
Big data analysis gives ability to ask better questions now, and hopefully answer questions in the future. #ismppam13
Effectiveness is the fourth hurdle for biopharma treatments, after safety, efficacy and quality. #ismppam13
@RussellTraynor: So how do we get these analytical windows to physicians? pharmaphorum.com/2013/03/13/… #ismppam13
So how do we get these analytical windows to physicians? pharmaphorum.com/2013/03/13/… #ismppam13
Change to data-intensive approach will also require change at regulatory level. Reproducibility will be key to this. #ismppam13
For big data to really impact medicine and patient care, there is need for cultural change as well as technical. #ismppam13
Data-intensive science will ultimately transform both scientific culture and publications. Move from papers to 'live' science #ismppam13